Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
J
Junji Tsurutani
Showa University(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
360
Papers
18.4K
Citations
53
h-index
149
i10-index
Junji Tsurutani is an academic researcher from Showa University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Lung Cancer Treatments and Mutations. The author has an h-index of 53, co-authored 306 publications.
ORCID: 0000-0002-6260-6943Papers by this author
worksAntitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
2020 · Journal of Clinical Oncology · 797 citations
https://doi.org/10.1200/jco.19.02318
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
2020 · Cancer Discovery · 279 citations
https://doi.org/10.1158/2159-8290.cd-20-0215
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
2019 · The Lancet Oncology · 227 citations
https://doi.org/10.1016/s1470-2045(19)30088-9
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 · Journal of Clinical Oncology · 130 citations
https://doi.org/10.1200/jco.23.01909
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
2015 · The Lancet Oncology · 94 citations
https://doi.org/10.1016/s1470-2045(15)00411-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat